• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铂类药物、紫杉醇和伊立替康对卵巢透明细胞癌有效吗?抗癌药物诱导的γH2AX 检测到的 DNA 损伤。

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents.

机构信息

Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1, Uchimaru, Morioka, Iwate, 020-8505, Japan.

出版信息

J Ovarian Res. 2012 Jun 12;5(1):16. doi: 10.1186/1757-2215-5-16.

DOI:10.1186/1757-2215-5-16
PMID:22691365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3407784/
Abstract

OBJECTIVES

Differences in the incidences and types of DNA damage induced by antitumor agents for clear cell carcinoma (CCC) were determined in 2 ovarian CCC cell lines using γH2AX.

MATERIAL AND METHODS

The antitumor activity of anticancer agents, CDDP, CBDCA, PTX and SN-38, was examined using ovarian clear cell carcinoma cultured cell lines (OVISE and RMG-I). After culture, each cell line was treated with each anticancer agent, the cells were collected, fixed, and then reacted with the anti-γH2AX antibody. γH2AX and nuclear DNA were then simultaneously detected by flow cytometry using FITC and propidium iodide, respectively, to determine γH2AX in each cell cycle phase.

RESULTS

After administration of CDDP, DNA damage was frequent in S-phase cells, while cell-cycle arrest occurred in the G1 and G2/M phases and γH2AX did not increase in CDDP-resistant cells. Sensitivities to CDDP and CBDCA differed between the two cell lines. The antitumor effect of PTX is induced by G2/M arrest, and combination treatment with CBDCA, inducing DNA damage in G2/M-phase cells, might be effective.

CONCLUSIONS

This is the first study in Japan to evaluate the antitumor activity of anticancer agents by focusing on the relationship between the cell cycle and DNA damage using γH2AX as an indicator. The immunocytochemical method used in this study detects γH2AX, which indicates DNA damage even at very low concentrations and with high sensitivity. Therefore, a promising method of easily and rapidly identifying agents potentially effective against CCC.

摘要

目的

使用 γH2AX 测定两种卵巢透明细胞癌细胞系中抗肿瘤药物引起的 DNA 损伤的发生率和类型的差异。

材料和方法

使用卵巢透明细胞癌培养细胞系(OVISE 和 RMG-I)检查抗癌药物顺铂(CDDP)、卡铂(CBDCA)、紫杉醇(PTX)和 SN-38 的抗肿瘤活性。培养后,用每种抗癌药物处理每个细胞系,收集细胞,固定,然后用抗 γH2AX 抗体反应。然后通过流式细胞术分别使用 FITC 和碘化丙啶同时检测 γH2AX 和核 DNA,以确定每个细胞周期阶段的 γH2AX。

结果

顺铂给药后,S 期细胞中 DNA 损伤频繁,而 G1 和 G2/M 期出现细胞周期停滞,并且 CDDP 耐药细胞中 γH2AX 没有增加。两种细胞系对 CDDP 和 CBDCA 的敏感性不同。PTX 的抗肿瘤作用是通过 G2/M 期阻滞诱导的,与 CBDCA 联合治疗,诱导 G2/M 期细胞中的 DNA 损伤,可能是有效的。

结论

这是日本首次使用 γH2AX 作为指标,通过评估细胞周期与 DNA 损伤之间的关系来评估抗癌药物抗肿瘤活性的研究。本研究中使用的免疫细胞化学方法检测 γH2AX,即使在非常低的浓度下也能高度敏感地指示 DNA 损伤。因此,这是一种很有前途的方法,可以快速、简便地识别对 CCC 可能有效的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/61f9c89fcdc8/1757-2215-5-16-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/f4e43f9694df/1757-2215-5-16-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/b41fc6c3f58e/1757-2215-5-16-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/4af67bb54c60/1757-2215-5-16-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/6fc29c602078/1757-2215-5-16-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/61f9c89fcdc8/1757-2215-5-16-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/f4e43f9694df/1757-2215-5-16-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/b41fc6c3f58e/1757-2215-5-16-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/4af67bb54c60/1757-2215-5-16-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/6fc29c602078/1757-2215-5-16-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afa1/3407784/61f9c89fcdc8/1757-2215-5-16-5.jpg

相似文献

1
Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents.铂类药物、紫杉醇和伊立替康对卵巢透明细胞癌有效吗?抗癌药物诱导的γH2AX 检测到的 DNA 损伤。
J Ovarian Res. 2012 Jun 12;5(1):16. doi: 10.1186/1757-2215-5-16.
2
Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX.使用 DNA 损伤标志物 γH2AX 分析吉西他滨和顺铂对卵巢透明细胞癌的抗肿瘤活性。
Onco Targets Ther. 2013 Jul 17;6:901-7. doi: 10.2147/OTT.S44021. Print 2013.
3
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.卵巢透明细胞癌对抗癌药物的敏感性及耐药机制
Jpn J Cancer Res. 2002 Jun;93(6):723-8. doi: 10.1111/j.1349-7006.2002.tb01312.x.
4
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.PM01183(鲁比卡丁)作为单一药物或与其他抗癌药物联合用于卵巢透明细胞癌的临床前研究。
PLoS One. 2016 Mar 17;11(3):e0151050. doi: 10.1371/journal.pone.0151050. eCollection 2016.
5
Chloroquine reverses chemoresistance via upregulation of p21 and autophagy inhibition in ovarian cancer.氯喹通过上调 p21 和抑制自噬逆转卵巢癌的化疗耐药性。
Cell Death Dis. 2020 Dec 4;11(12):1034. doi: 10.1038/s41419-020-03242-x.
6
Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.铂类药物治疗骨肉瘤:顺铂与卡铂对人骨肉瘤细胞系的疗效比较
Med Pediatr Oncol. 2002 Dec;39(6):573-80. doi: 10.1002/mpo.10076.
7
DNA-dependent protein kinase: effect on DSB repair, G2/M checkpoint and mode of cell death in NSCLC cell lines.DNA 依赖性蛋白激酶:对非小细胞肺癌细胞系中 DSB 修复、G2/M 检验点和细胞死亡方式的影响。
Int J Radiat Biol. 2019 Sep;95(9):1205-1219. doi: 10.1080/09553002.2019.1642536. Epub 2019 Jul 24.
8
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.联合使用曲贝替定、伊立替康或拓扑替康对卵巢透明细胞癌细胞具有协同作用。
Int J Gynecol Cancer. 2014 Jun;24(5):829-37. doi: 10.1097/IGC.0000000000000143.
9
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX.由γH2AX水平定义的细胞周期G2期新的不同区室。
Cell Cycle. 2015;14(20):3261-9. doi: 10.1080/15384101.2015.1087617.
10
Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.人卵巢癌细胞中铂类抗癌药物获得性耐药的建立与表征
Jpn J Cancer Res. 1995 Jan;86(1):88-94. doi: 10.1111/j.1349-7006.1995.tb02992.x.

引用本文的文献

1
SORBS1 Knockdown Resists S/G2 Arrest and Apoptosis Caused by Polyphyllin H-Induced DNA Damage in Pancreatic Cancer.SORBS1基因敲低可抵抗重楼皂苷H诱导的胰腺癌DNA损伤所引起的S/G2期阻滞和细胞凋亡。
Oncol Res. 2025 Aug 28;33(9):2491-2506. doi: 10.32604/or.2025.064454. eCollection 2025.
2
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.难治性卵巢癌的新型治疗策略:透明细胞癌和黏液性癌
Cancers (Basel). 2021 Dec 4;13(23):6120. doi: 10.3390/cancers13236120.
3
Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX.

本文引用的文献

1
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.每周一次密集剂量紫杉醇联合每3周一次卡铂治疗晚期卵巢癌:一项3期、开放标签、随机对照试验。
Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18.
2
H2AX: functional roles and potential applications.H2AX:功能作用与潜在应用
Chromosoma. 2009 Dec;118(6):683-92. doi: 10.1007/s00412-009-0234-4. Epub 2009 Aug 26.
3
H2AX is required for cell cycle arrest via the p53/p21 pathway.
使用 DNA 损伤标志物 γH2AX 分析吉西他滨和顺铂对卵巢透明细胞癌的抗肿瘤活性。
Onco Targets Ther. 2013 Jul 17;6:901-7. doi: 10.2147/OTT.S44021. Print 2013.
通过p53/p21途径使细胞周期停滞需要H2AX。
Mol Cell Biol. 2009 May;29(10):2828-40. doi: 10.1128/MCB.01830-08. Epub 2009 Mar 9.
4
GammaH2AX and cancer.γH2AX与癌症
Nat Rev Cancer. 2008 Dec;8(12):957-67. doi: 10.1038/nrc2523. Epub 2008 Nov 13.
5
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.接受紫杉醇-卡铂或伊立替康-顺铂治疗的卵巢透明细胞癌患者的无进展生存期和总生存期:回顾性分析
Int J Clin Oncol. 2007 Aug;12(4):256-60. doi: 10.1007/s10147-007-0670-1. Epub 2007 Aug 20.
6
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.盐酸伊立替康和顺铂辅助化疗用于卵巢透明细胞癌
Oncol Rep. 2006 Dec;16(6):1301-6.
7
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.盐酸伊立替康(CPT-11)与丝裂霉素C作为卵巢透明细胞腺癌的一线化疗方案。
Gynecol Oncol. 2005 Jun;97(3):893-7. doi: 10.1016/j.ygyno.2005.03.009.
8
Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines.培养的卵巢癌细胞系中癌基因产物表达与抗癌药物耐药性之间的相关性。
Hum Cell. 2003 Sep;16(3):131-9. doi: 10.1111/j.1749-0774.2003.tb00145.x.
9
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.卡铂与紫杉醇联合方案对比顺铂与紫杉醇联合方案用于 III 期卵巢癌最佳减瘤术后患者的 III 期临床试验:一项妇科肿瘤学组研究
J Clin Oncol. 2003 Sep 1;21(17):3194-200. doi: 10.1200/JCO.2003.02.153. Epub 2003 Jul 14.
10
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.卵巢透明细胞癌对抗癌药物的敏感性及耐药机制
Jpn J Cancer Res. 2002 Jun;93(6):723-8. doi: 10.1111/j.1349-7006.2002.tb01312.x.